Clinical and Quantitative Sciences, North Wales, Pennsylvania, USA.
MAbs. 2009 Jan-Feb;1(1):67-70. doi: 10.4161/mabs.1.1.7359.
Monoclonal antibodies (mAbs) as a class of novel oncology therapeutics are demonstrating clinical efficacy as measured by tumor response (shrinkage in tumor size), and prolongations in progression-free survival (PFS) and overall survival (OS). However, clinical benefits are often limited to when antibodies are used in combination with chemotherapy or radiation modalities, with tumor responses only seen in a fraction of patients, and improvements in PFS and OS are incremental.1 The potential of mAbs and mAb constructs has yet to be fully exploited for maximal clinical benefit. New approaches to further improve the effectiveness of these mAb therapies include (1) selection of patients who may derive the most benefit based on the molecular characteristics of their tumors; (2) improvements in biodistribution to maximize delivery of mAbs to susceptible tumor cells; and (3) optimization of antibody immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC).
单克隆抗体 (mAbs) 作为一类新型肿瘤治疗药物，其临床疗效已得到证实，表现为肿瘤应答（肿瘤体积缩小）和无进展生存期 (PFS) 和总生存期 (OS) 的延长。然而，临床获益通常仅限于抗体与化疗或放射治疗联合使用时，只有一部分患者出现肿瘤应答，且 PFS 和 OS 的改善是渐进的。1 mAbs 和 mAb 构建物的潜力尚未得到充分利用，以获得最大的临床获益。进一步提高这些 mAb 治疗效果的新方法包括：(1) 根据肿瘤的分子特征选择可能受益最大的患者；(2) 改善生物分布，以最大限度地将 mAbs 递送至易受影响的肿瘤细胞；(3) 优化抗体免疫效应机制，如抗体依赖性细胞毒性 (ADCC)。
